EMA Authorised: Fingolimod Mylan (Fingolimod) — Mylan Pharmaceuticals Limited

View source ↗

Summary

Fingolimod Mylan has been authorised for multiple sclerosis, relapsing-remitting, by the EMA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Fingolimod Mylan (Fingolimod)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Mylan Pharmaceuticals Limited. Decision date: 08/06/2026